You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

obinutuzumab

Showing 51 - 75 of 166
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Mantle Cell Lymphoma Trial in Duarte (drug, procedure, biological)

Not yet recruiting
  • Mantle Cell Lymphoma
  • Duarte, California
    City of Hope Medical Center
Sep 20, 2023

Follicular Lymphoma Trial in Chicago (Venetoclax, Obinutuzumab, CC-486)

Recruiting
  • Follicular Lymphoma
  • Chicago, Illinois
    University of Chicago Medical Center
Nov 12, 2021

Mantle Cell Lymphoma Trial in Warszawa, Wroclaw (Obinutuzumab)

Terminated
  • Mantle Cell Lymphoma
  • Obinutuzumab
  • Warszawa, Poland
  • +1 more
Dec 23, 2021

Metastatic Colorectal Cancer Trial in Worldwide (RO7122290, Cibisatamab, Obinutuzumab)

Recruiting
  • Metastatic Colorectal Cancer
  • Toronto, Ontario, Canada
  • +15 more
Jan 13, 2023

Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma Trial in Duarte

Not yet recruiting
  • Blastoid Variant Mantle Cell Lymphoma
  • +2 more
  • Biopsy
  • +8 more
  • Duarte, California
    City of Hope Medical Center
May 15, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Boston (Venetoclax, Obinutuzumab, Rituximab)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Dec 5, 2022

Ann Arbor Stage II Grade 1 Follicular Lymphoma, Ann Arbor Stage II Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 1

Active, not recruiting
  • Ann Arbor Stage II Grade 1 Follicular Lymphoma
  • +12 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 18, 2022

Colorectal Cancer Trial in Worldwide (Obinutuzumab, Atezolizumab, Cibisatamab)

Active, not recruiting
  • Colorectal Cancer
  • Obinutuzumab
  • +3 more
  • Los Angeles, California
  • +12 more
Aug 19, 2022

B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, Grade 1 Follicular Lymphoma,

Active, not recruiting
  • B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
  • +11 more
  • Atlanta, Georgia
  • +1 more
Apr 18, 2022

Lymphoma, Large B-Cell, Diffuse Trial in Austria (Venetoclax, Obinutuzumab)

Completed
  • Lymphoma, Large B-Cell, Diffuse
  • Graz, Austria
  • +5 more
Feb 15, 2022

Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Boston (Glofitamab, Obinutuzumab, Polatuzumab Vedotin)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Richter's Transformation
  • Boston, Massachusetts
  • +1 more
Sep 12, 2023

Lymphoma, Non-Hodgkin Trial in Worldwide (CC-99282, Obinutuzumab)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Boston, Massachusetts
  • +17 more
Aug 1, 2022

DLBCL Trial in Suzhou (Chidamide, Azacitidine, obinutuzumab)

Recruiting
  • Diffuse Large B-Cell Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Apr 10, 2023

Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma Trial in Atlanta (drug, biological,

Recruiting
  • Grade 1 Follicular Lymphoma
  • +7 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Dec 7, 2021

Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia Trial in Columbus (drug, biological, other)

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Refractory Chronic Lymphocytic Leukemia
  • Bcl-2 Inhibitor GDC-0199
  • +5 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Oct 29, 2021

B-cell Lymphoid Malignancies Trial in Australia, Korea, Republic of, United States (Zanubrutinib, Obinutuzumab)

Completed
Has Results
  • B-cell Lymphoid Malignancies
  • Fort Myers, Florida
  • +14 more
Mar 1, 2022

Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) Trial in Japan (Venetoclax, Ibrutinib, Obinutuzumab)

Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Small Lymphocytic Lymphoma (SLL)
  • Nagoya-shi, Aichi, Japan
  • +19 more
Jan 25, 2023

Hairy Cell Leukemia, Leukemia, Leukemia, Hairy Cell Trial in United States (Vemurafenib, Obinutuzumab)

Active, not recruiting
  • Hairy Cell Leukemia
  • +2 more
  • New Haven, Connecticut
  • +8 more
Feb 7, 2022

Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Trial in Worldwide (Acalabrutinib, Venetoclax, Obinutuzumab)

Recruiting
  • Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
  • Tucson, Arizona
  • +40 more
Dec 20, 2022

Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in United States (FT596, Cyclophosphamide, Fludarabine)

Recruiting
  • Lymphoma, B-Cell
  • Chronic Lymphocytic Leukemia
  • Chicago, Illinois
  • +8 more
Jun 21, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Boston (Venetoclax, Obinutuzumab, Acalabrutinib)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Boston, Massachusetts
  • +2 more
Aug 9, 2021

Relapsed/Refractory Marginal Zone Lymphoma Trial in Westbury (Zanubrutinib, Rituximab, Lenalidomide)

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Westbury, New York
    Clinical Research Alliance, Inc.
Nov 14, 2022

Non-Hodgkin's Lymphoma Trial in Australia, Italy, United States (Obinutuzumab, Rituximab, Polatuzumab Vedotin)

Completed
  • Non-Hodgkin's Lymphoma
  • Obinutuzumab
  • +3 more
  • Tucson, Arizona
  • +22 more
Aug 5, 2022

Advanced Follicular Lymphoma Trial in Worldwide (Obinutuzumab, Bendamustine, Cyclophosphamide)

Active, not recruiting
Has Results
  • Advanced Follicular Lymphoma
  • Obinutuzumab
  • +5 more
  • Boulder, Colorado
  • +33 more
Nov 21, 2022

Lymphoma Trial in Beijing, Shanghai City, Seoul (Obinutuzumab, Glofitamab, Rituximab)

Recruiting
  • Lymphoma
  • Obinutuzumab
  • +5 more
  • Beijing, China
  • +2 more
Oct 12, 2023